Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

Melanoma is a type of skin cancer that starts when pigment cells in the skin grow uncontrollably, rising for the last 30 ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

That's why we made it our mission to identify the absolute best cortisol supplements on the market in 2024. We've analyzed ...

The research team has already found that preserving lymph nodes during treatment initiation helps the body's immune system ...

Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM: Rahway, New Jersey Thursday, September 19, 2024, ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune ...

Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024WALTHAM, Mass., Sept.

A Wyss Institute team has been selected to develop a broad-spectrum antimicrobial therapeutic under a contract from the DARPA-SHIELD program.

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’Topline safety data of SB101 Phase 1 study expected ...

High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall ...